The effectiveness of piracetam in vertigo
- PMID: 10338110
- DOI: 10.1055/s-2007-979238
The effectiveness of piracetam in vertigo
Abstract
Vertigo is a sensation of altered orientation in space and may be defined as an illusion of movement. It is a subjective symptom and therefore difficult to assess. Examination and diagnosis remain difficult. Although treatment should be directed at the underlying cause or disorder, the origin of vertigo is frequently unknown or untreatable. Pharmacotherapy is required for symptomatic treatment. Piracetam has been shown to be effective in vertigo of both central and peripheral origin. It is thought to act on vestibular and oculomotor nuclei in the brain stem and thus on the central control of balance enhancing mechanisms of compensation and habituation. This review of double-blind trials shows that piracetam alleviates vertigo after head injury, vertigo of central origin as, for example, in vertebrobasilar insufficiency and in peripheral vestibular disorders, especially in middle-aged and elderly subjects. Piracetam decreases the frequency but probably not the severity of exacerbations in patients with chronic or recurrent vertigo. The usual dosage of piracetam in vertigo is 2.4-4.8 g daily. Tolerability of piracetam is good and adverse effects have been mild and infrequent.
Similar articles
-
[The effect of pharmacological treatment in the compensation of vertigo].An Otorrinolaringol Ibero Am. 1999;26(3):271-91. An Otorrinolaringol Ibero Am. 1999. PMID: 10394686 Clinical Trial. Spanish.
-
The efficacy of piracetam in vertigo. A double-blind study in patients with vertigo of central origin.Arzneimittelforschung. 1980;30(11):1947-9. Arzneimittelforschung. 1980. PMID: 7006617 Clinical Trial.
-
Piracetam in the treatment of myoclonus: an overview.Acta Neurol Belg. 1996 Dec;96(4):270-80. Acta Neurol Belg. 1996. PMID: 9008776 Review.
-
Efficacy and tolerability of a fixed low-dose combination of cinnarizine and dimenhydrinate in the treatment of vertigo: a 4-week, randomized, double-blind, active- and placebo-controlled, parallel-group, outpatient study.Clin Ther. 2007 Jan;29(1):84-98. doi: 10.1016/j.clinthera.2007.01.010. Clin Ther. 2007. PMID: 17379049 Clinical Trial.
-
Approach to the dizzy patient.Baillieres Clin Neurol. 1994 Nov;3(3):453-65. Baillieres Clin Neurol. 1994. PMID: 7874402 Review.
Cited by
-
Oral Piracetam vs Betahistine in Outpatient Management of Peripheral Vertigo; a Randomized Clinical Trial.Arch Acad Emerg Med. 2019 Jan 23;7(1):e9. eCollection 2019 Winter. Arch Acad Emerg Med. 2019. PMID: 30847444 Free PMC article.
-
Efficacy and Pharmacological Appropriateness of Cinnarizine and Dimenhydrinate in the Treatment of Vertigo and Related Symptoms.Int J Environ Res Public Health. 2021 Apr 30;18(9):4787. doi: 10.3390/ijerph18094787. Int J Environ Res Public Health. 2021. PMID: 33946152 Free PMC article.
-
Improved mitochondrial function in brain aging and Alzheimer disease - the new mechanism of action of the old metabolic enhancer piracetam.Front Neurosci. 2010 Sep 7;4:44. doi: 10.3389/fnins.2010.00044. eCollection 2010. Front Neurosci. 2010. PMID: 20877425 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical